The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases
| Autor: | Anne Marie Miller, Anja Schneider, Tomasz Gabryelewicz, Marcel M. Verbeek, Lucilla Parnetti, Tormod Fladby, Alexandre de Mendonça, Charlotte E. Teunissen, Fay Betsou, Uroš Rot, Walter Maetzler, Henrik Zetterberg, Frederic Brosseron, Sylvain Lehmann, Alberto Lleó, José Luis Molinuevo, Luka Kulic, Anja Hviid Simonsen, Frans R.J. Verhey, Enrica Cavedo, Philip Scheltens, Peter Koson, Hakan Gurvit, Babette L.R. Reijs, Inês Baldeiras, Piotr Lewczuk, Lutz Froelich, Brit Mollenhauer, Elisabeth Kapaki, Bengt Winblad, Fabrizio Tagliavini, Kaj Blennow, Magda Tsolaki, Nikolai Goncharenko, Pieter Jelle Visser, Marzena Zboch |
|---|---|
| Přispěvatelé: | Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Promovendi MHN, Hersenen & Gedrag, Psychiatrie & Neuropsychologie, MUMC+: MA Med Staf Spec Psychiatrie (9), RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Clinical chemistry, Neurology, NCA - neurodegeneration |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Oncology
cognition Pathology Parkinson's disease [SDV]Life Sciences [q-bio] frontotemporal dementia lcsh:RC346-429 Faculty of Medicine Medizinische Fakultät diffuse Lewy body disease Biomarker discovery ComputingMilieux_MISCELLANEOUS Original Research Alzheimer's disease biological marker Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3] Biobank 3. Good health multiinfarct dementia Parkinson disease biobank Neurology neurodegenerative disorders Alzheimer's disease (AD) prognostic assessment blood sampling diagnostic procedure cerebrospinal fluid dementia Alzheimer’s disease Parkinson’s disease body fluids Alzheimer disease Frontotemporal dementia medicine.medical_specialty Article Progressive supranuclear palsy mild cognitive impairment Internal medicine mental disorders medicine ddc:6 Dementia degenerative disease ddc:610 Body fluids Cerebrospinal fluid Neurodegenerative disorders Neurology (clinical) Vascular dementia plasma lcsh:Neurology. Diseases of the nervous system standardization body fluid business.industry Dementia with Lewy bodies health care facility progressive supranuclear palsy assay medicine.disease validation process Shy Drager syndrome business Neuroscience |
| Zdroj: | Frontiers in Neurology Frontiers in Neurology, Frontiers, 2015, 6, ⟨10.3389/fneur.2015.00216⟩ Frontiers in Neurology, 6 Frontiers in Neurology, 6:216. Frontiers Media S.A. Frontiers in Neurology.-Lausanne : Frontiers Media SA; 2015.-S.216:1-216:7. Frontiers in Neurology, Vol 6 (2015) Reijs, B L R, Teunissen, C E, Goncharenko, N, Betsou, F, Blennow, K, Baldeiras, I, Brosseron, F, Cavedo, E, Fladby, T, Froelich, L, Gabryelewicz, T, Gurvit, H, Kapaki, E, Koson, P, Kulic, L, Lehmann, S, Lewczuk, P, Lleo, A, Maetzler, W, de Mendonca, A, Miller, A M, Molinuevo, J L, Mollenhauer, B, Parnetti, L, Rot, U, Schneider, A, Simonsen, A H, Tagliavini, F, Tsolaki, M, Verbeek, M M, Verhey, F R J, Zboch, M, Winblad, B, Scheltens, P, Zetterberg, H & Visser, P J 2015, ' The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases ', Frontiers in Neurology, vol. 6, 216 . https://doi.org/10.3389/fneur.2015.00216 r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Frontiers in neurology 6, 216 (2015). doi:10.3389/fneur.2015.00216 FRONTIERS IN NEUROLOGY |
| ISSN: | 1664-2295 |
| Popis: | Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multicenter study, funded by the EU Joint Programme-Neurodegenerative Disease Research, which aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer's disease (AD) and Parkinson's disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized pre-analytical procedures and stored at Integrated BioBank of Luxembourg. The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia, multiple system atrophy, progressive supranuclear palsy, PD, PD with dementia, and dementia with Lewy bodies. The virtual biobank contains information on over 8,600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank. © 2015 Reijs, Teunissen, Goncharenko, Betsou, Blennow, Baldeiras, Brosseron, Cavedo, Fladby, Froelich, Gabryelewicz, Gurvit, Kapaki, Koson, Kulic, Lehmann, Lewczuk, Lleó, Maetzler, de Mendonça, Miller, Molinuevo, Mollenhauer, Parnetti, Rot, Schneider, Simonsen, Tagliavini, Tsolaki, Verbeek, Verhey, Zboch, Winblad, Scheltens, Zetterberg and Visser. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|